INGREZZA (valbenazine)

About Neurocrine Biosciences

Founded in 1992, Neurocrine Biosciences has evolved from a research-focused biotech into a successful commercial company with over $1.5 billion in annual revenue. Their expertise in neuroscience drug development has produced breakthrough treatments like INGREZZA for tardive dyskinesia and a promising pipeline including programs for Parkinson's disease, schizophrenia, and endometriosis. The company combines strong commercial execution with continued innovation in CNS therapeutics.

About Neurocrine Biosciences

Founded in 1992, Neurocrine Biosciences has evolved from a research-focused biotech into a successful commercial company with over $1.5 billion in annual revenue. Their expertise in neuroscience drug development has produced breakthrough treatments like INGREZZA for tardive dyskinesia and a promising pipeline including programs for Parkinson's disease, schizophrenia, and endometriosis. The company combines strong commercial execution with continued innovation in CNS therapeutics.

Therapeutic Areas